2018 American Transplant Congress
Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
Introduction: Ischemia reperfusion injury (IRI) contributes to delayed graft function (DGF). IRI/DGF in HLA-sensitized (HS) patients likely activates innate and memory injury pathways that may…2018 American Transplant Congress
Identifying Patients with CPRA>99.95% Likely to Be Offered Deceased Donor Kidneys
Emory Transplant Center, Atlanta, GA.
The implementation of the new kidney allocation system and priority of kidneys for cPRA=100% subjects revealed a hierarchy difference in allocation to patients with cPRA=99.45%-100%.…2018 American Transplant Congress
Inferior Patient and Graft Survival in Highly Sensitized Adult Kidney Transplant Recipients with a Prior Transplant Compared to Pediatric Kidney Transplant Recipients: An Analysis of OPTN Data
Under the current kidney allocation system (KAS), pediatric (PED) renal transplant (RTx) candidates have a priority to kidneys from KDPI <35% donors. However, that excludes…2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…2018 American Transplant Congress
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
Columbia University, New York.
INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…2017 American Transplant Congress
Pre-Transplant Evaluation of KSORTSM to Assess Risk for Rejection in Highly Sensitized Patients.
Study purpose: To investigate the kSORTSM molecular expression assay for immune risk assessment in renal transplant (tx) recipients prior to tx for correlation of pre-tx…2017 American Transplant Congress
Desensitization versus Deceased Donor Kidney Transplantation: What to Choose When Both Become Available?
1UCSF, San Francisco; 2Johns Hopkins, Baltimore; 3NYU, New York
Kidney allocation system changes have improved deceased donor kidney transplant (DDKT) access for highly sensitized patients. For patients with a willing live donor but requiring…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 15
- Next Page »